Pfizer Head Gives Insight into Big Pharma Versus Biotech

10 October

In October 2005, veski and the BioMelbourne Network held a CEO luncheon featuring Dr David Alker, the Senior Research Fellow, Head - Discovery Staffing Group, Pfizer Global Research and Development, Sandwich Laboratories in the United Kingdom.

Dr Alker spoke about how technical convergence and innovation partnership models are affecting the big pharma. He also gave the audience the benefit of his observations on how Australian talent moving to the major northern hemisphere markets to further their careers and skill levels, can engage with the big pharmaceutical companies.

What's On

March

S M T W T F S
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
31
 
 
 
 

veski connection members in the news

Apr 2020 | Royal Society

Prof Jane Visavader, 2018 Victoria Prize for Science & Innovation recipient, elected to the Royal Societyin 2020

“The real benefit of increasing fabrication rates is the transition from prototyping, making one offs, to actually going into production.”

Assoc Prof Timothy Scott

Tweets from @veskiorg